RxDoctor Payments DataLook up a doctor →

Rupali Paradkar, MD

Internal Medicine · Bentonville, ARNPI 1215172713

Payments from drug & device makers

$11,450in general payments, 2019–2025

Across 779 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$974
  • Pfizer$969
  • GSK$796
  • Novo Nordisk$781
  • Lilly USA, LLC$761
  • plus $6K from 50 others

What the payments were for

  • Food & beverage$11,450100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)122$1,649
Amgen58$974
Pfizer76$969
GSK79$796
Novo Nordisk56$781
Lilly USA, LLC56$761
AstraZeneca24$665
Abbott35$447
Johnson & Johnson25$398
Bayer18$350
Boehringer Ingelheim15$279
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$262
Kowa Pharmaceuticals America, Inc.23$255
Astellas Pharma US Inc15$252
Merck14$207
Amarin Pharma, Inc.8$157
Biohaven Pharmaceutical Holding Company Ltd.11$143
Biohaven Pharmaceuticals, Inc.9$138
Exact Sciences9$135
Sumitomo Pharma America, Inc.7$126
Mylan Specialty L.p.8$118
Teva Pharmaceuticals USA, Inc.7$113
Esperion Therapeutics, Inc.8$102
E.r. Squibb & Sons, L.L.C.7$100
Arbor Pharmaceuticals, Inc.6$99
Vanda Pharmaceuticals Inc.4$94
Radius Health, Inc.5$89
Dexcom, Inc.5$82
Dynavax Technologies Corporation5$80
Phathom Pharmaceuticals, Inc.5$74
Takeda Pharmaceuticals U.S.A., Inc.4$68
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$57
Novartis4$51
Ironshore Pharmaceuticals Inc.3$49
Daiichi Sankyo Inc.2$48
Eisai Inc.3$48
Sanofi-aventis U.S. LLC3$36
Genentech USA, Inc.2$34
Alfasigma USA, Inc.2$33
Axsome Therapeutics, Inc.1$33
Sanofi Pasteur Inc.1$30
Bausch Health US, LLC1$29
Amneal Pharmaceuticals LLC2$27
Averitas Pharma Inc.1$23
Hikma Pharmaceuticals USA1$22
Inspire Medical Systems, Inc.1$20
Travere Therapeutics, Inc.1$19
Antares Pharma, Inc.1$18
Supernus Pharmaceuticals, Inc.1$18
Viatris Specialty LLC1$16
Currax Pharmaceuticals LLC1$16
Otsuka America Pharmaceutical, Inc.1$14
Dermira, Inc.1$12
Sunovion Pharmaceuticals Inc.1$12
Idorsia Pharmaceuticals US Inc1$12
Ironwood Pharmaceuticals, Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,450 in reported general payments places this provider in the 95th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$165,601
Medicare patients
369
Services billed
3,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$161,231
EliquisApixaban136$143,641
TrulicityDulaglutide70$92,303
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$75,832
MounjaroTirzepatide64$74,920
JardianceEmpagliflozin44$70,391
XareltoRivaroxaban51$53,465
FarxigaDapagliflozin Propanediol26$41,763
Tresiba Flextouch U-200Insulin Degludec26$41,561
MyrbetriqMirabegron47$39,211
RybelsusSemaglutide17$33,013
Breo ElliptaFluticasone/Vilanterol31$16,713
LinzessLinaclotide13$15,365
Bydureon BciseExenatide Microspheres12$11,803
Tresiba Flextouch U-100Insulin Degludec15$9,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$781$194,244133 claims
Lilly USA, LLCTrulicity, Mounjaro$761$167,223134 claims
PfizerEliquis, Paxlovid$969$146,499149 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$796$99,314119 claims
Boehringer IngelheimJardiance$279$70,39144 claims
Johnson & JohnsonXarelto$398$53,46551 claims
AstraZenecaFarxiga$665$41,76326 claims
Astellas Pharma US IncMyrbetriq$252$39,21147 claims
AbbVieLinzess$1,649$15,36513 claims
MerckBelsomra$207$7,23615 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$4,951656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Bentonville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →